Back to Search Start Over

Cardiac resynchronization therapy with or without defibrillator in patients with heart failure

Authors :
Schrage, Benedikt
Lund, Lars H.
Melin, Michael
Benson, Lina
Uijl, Alicia
Dahlström, Ulf
Braunschweig, Frieder
Linde, Cecilia
Savarese, Gianluigi
Schrage, Benedikt
Lund, Lars H.
Melin, Michael
Benson, Lina
Uijl, Alicia
Dahlström, Ulf
Braunschweig, Frieder
Linde, Cecilia
Savarese, Gianluigi
Publication Year :
2022

Abstract

Aims Randomized data on the efficacy/safety of cardiac resynchronization therapy with vs. without defibrillator (CRT-D,-P) in heart failure with reduced ejection fraction (HFrEF) are scarce. We aimed to evaluate survival associated with use of CRT-D vs. CRT-P in a contemporary cohort with HFrEF. Methods and results Patients from Swedish HF Registry treated with CRT-D/CRT-P and fulfilling criteria for primary prevention defibrillator use were included. Logistic regression was used to evaluate predictors of CRT-D non-use. All-cause mortality was compared in CRT-D vs. CRT-P by Cox regression in a 1 : 1 propensity-score-matched cohort. Of 1988 patients with CRT, 1108 (56%) had CRT-D and 880 (44%) CRT-P. Older age, higher ejection fraction (EF), female sex, and the lack of referral to HF nurse-led outpatient clinic were major determinants of CRT-D non-use. After matching, 645 CRT-D patients were compared with 645 with CRT-P. The CRT-D use was associated with lower 1- and 3-year all-cause mortality [hazard ratio (HR):0.76, 95% confidence interval (CI):0.58-0.98; HR: 0.82, 95% CI: 0.68-0.99, respectively]. Results were consistent in all pre-specified subgroups except for CRT-D use being associated with lower 3-year mortality in patients with an EF < 30% but not in those with an EF >= 30% (HR: 0.73, 95% CI: 0.59-0.89 and HR: 1.24, 95% CI: 0.83-1.85, respectively; P-interaction = 0.02). Conclusion In a contemporary HFrEF cohort, CRT-D was associated with lower mortality compared with CRT-P. The CRT-D use was less likely in older patients, females, and in patients not referred to HF nurse-led outpatient clinic. Our findings support the use of CRT-D vs. CRT-P in HFrEF, in particular with severely reduced EF.<br />Funding Agencies|Boston ScientificBoston Scientific; EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking BigData@Heart [116074]; German Research FoundationGerman Research Foundation (DFG); Else Kroner-Fresenius-Stiftung

Details

Database :
OAIster
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1312843183
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1093.europace.euab233